• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Differentiating biochemical from clinical heparin resistance in COVID-19.

作者信息

Lisman Ton, Thachil Jecko

机构信息

Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, BA33, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands.

Department of Haematology, Manchester University Hospitals, Oxford road, Manchester, UK.

出版信息

J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.

DOI:10.1007/s11239-020-02259-5
PMID:32880796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7471526/
Abstract
摘要

相似文献

1
Differentiating biochemical from clinical heparin resistance in COVID-19.区分COVID-19中生化性与临床性肝素抵抗
J Thromb Thrombolysis. 2020 Nov;50(4):1015-1016. doi: 10.1007/s11239-020-02259-5.
2
Heparin failure and COVID-19: Should we explore other anticoagulants? An observational report regarding in-vitro recovery of anticoagulant action in COVID-19 patients in intensive care.肝素失效与新冠病毒病：我们是否应探索其他抗凝剂？一份关于重症监护病房新冠病毒病患者抗凝作用体外恢复情况的观察报告
Thromb Res. 2020 Nov;195:226-227. doi: 10.1016/j.thromres.2020.08.010. Epub 2020 Aug 9.
3
A Case of Covid-19 Patient with Acute Limb Ischemia and Heparin Resistance.一例新冠肺炎合并急性肢体缺血及肝素抵抗患者的病例
Ann Vasc Surg. 2020 Oct;68:88-92. doi: 10.1016/j.avsg.2020.06.046. Epub 2020 Jun 24.
4
Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.肝素在治疗新冠肺炎患者中的抗凝和抗心律失常作用。
J Thromb Haemost. 2020 Aug;18(8):2073-2075. doi: 10.1111/jth.14902.
5
The versatile heparin in COVID-19.新冠疫情中用途广泛的肝素。
J Thromb Haemost. 2020 May;18(5):1020-1022. doi: 10.1111/jth.14821. Epub 2020 Apr 27.
6
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?新冠病毒感染中的肺栓塞或肺血栓形成？使用高剂量肝素进行血栓预防的建议是否合理？
Thromb Haemost. 2020 Aug;120(8):1230-1232. doi: 10.1055/s-0040-1712097. Epub 2020 Apr 29.
7
Potential of heparin and nafamostat combination therapy for COVID-19.肝素与那法莫司他联合治疗新冠肺炎的潜力
J Thromb Haemost. 2020 Jun;18(6):1521-1522. doi: 10.1111/jth.14858. Epub 2020 May 6.
8
Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin.新型冠状病毒肺炎患者的肺栓塞及其基于低分子量肝素的治疗
Sao Paulo Med J. 2020 Jul-Aug;138(4):349-351. doi: 10.1590/1516-3180.2020.0221.r2.22072020.
9
Type and dose of heparin in Covid-19: Reply.新冠病毒病中肝素的类型和剂量：回复
J Thromb Haemost. 2020 Aug;18(8):2063-2064. doi: 10.1111/jth.14870. Epub 2020 May 11.
10
Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy.接受肝素治疗的COVID-19患者中抗肝素-PF4复合物抗体的检测。
Blood Transfus. 2020 Jul;18(4):328. doi: 10.2450/2020.0164-20.

引用本文的文献

1
Serial thrombin generation and exploration of alternative anticoagulants in critically ill COVID-19 patients: Observations from Maastricht Intensive Care COVID Cohort.重症新型冠状病毒肺炎患者的系列凝血酶生成及新型抗凝剂探索：来自马斯特里赫特重症监护新型冠状病毒肺炎队列的观察结果
Front Cardiovasc Med. 2022 Oct 6;9:929284. doi: 10.3389/fcvm.2022.929284. eCollection 2022.
2
Factor VIII, Fibrinogen and Heparin Resistance in COVID-19 Patients with Thromboembolism: How Should We Manage the Anticoagulation Therapy?新冠病毒肺炎血栓栓塞患者的凝血因子 VIII、纤维蛋白原与肝素抵抗：我们应如何管理抗凝治疗？
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221087692. doi: 10.1177/10760296221087692.
3
Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia.充足的抗凝血酶III水平可预测重症COVID-19肺炎患者的生存率。
Cureus. 2021 Oct 6;13(10):e18538. doi: 10.7759/cureus.18538. eCollection 2021 Oct.
4
Heparin - Messias or Verschlimmbesserung?肝素——救星还是越帮越忙？
J Thromb Haemost. 2021 Oct;19(10):2373-2382. doi: 10.1111/jth.15464. Epub 2021 Jul 29.
5
How we approach thrombosis risk in children with COVID-19 infection and MIS-C.我们如何应对新冠病毒感染和儿童多系统炎症综合征患儿的血栓形成风险。
Pediatr Blood Cancer. 2021 Jul;68(7):e29049. doi: 10.1002/pbc.29049. Epub 2021 May 6.
6
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.新冠肺炎患者的血栓前状态改变与疾病严重程度和死亡率相关。
Res Pract Thromb Haemost. 2020 Dec 6;5(1):132-141. doi: 10.1002/rth2.12462. eCollection 2021 Jan.

本文引用的文献

1
In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.COVID-19 患者抗凝治疗过程中体外高凝状态和体内凝血及纤溶持续激活。
J Thromb Haemost. 2020 Oct;18(10):2646-2653. doi: 10.1111/jth.15043. Epub 2020 Sep 1.
2
Hypoxia-An overlooked trigger for thrombosis in COVID-19 and other critically ill patients.缺氧——新冠病毒感染及其他重症患者中被忽视的血栓形成诱因
J Thromb Haemost. 2020 Nov;18(11):3109-3110. doi: 10.1111/jth.15029.
3
Thrombosis and coagulopathy in COVID-19: An illustrated review.新型冠状病毒肺炎中的血栓形成与凝血病：图文综述
Res Pract Thromb Haemost. 2020 Jul 11;4(5):744-751. doi: 10.1002/rth2.12400. eCollection 2020 Jul.
4
Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis.低纤维蛋白溶解状态和高凝血酶生成可能在 SARS-COV2 相关血栓形成中起主要作用。
J Thromb Haemost. 2020 Sep;18(9):2215-2219. doi: 10.1111/jth.15016. Epub 2020 Aug 11.
5
Coagulopathy in COVID-19.新型冠状病毒疾病中的凝血功能障碍。
J Thromb Haemost. 2020 Sep;18(9):2103-2109. doi: 10.1111/jth.14975. Epub 2020 Jul 21.
6
Heparin resistance in COVID-19 patients in the intensive care unit.COVID-19 患者在重症监护病房中肝素耐药。
J Thromb Thrombolysis. 2020 Aug;50(2):287-291. doi: 10.1007/s11239-020-02145-0.
7
Monitoring of heparins in antithrombin-deficient patients.抗凝血酶缺乏患者的肝素监测。
Thromb Res. 2019 Mar;175:8-12. doi: 10.1016/j.thromres.2019.01.007. Epub 2019 Jan 15.
8
Clinical Scenarios for Discordant Anti-Xa.抗Xa检测结果不一致的临床案例
Adv Hematol. 2016;2016:4054806. doi: 10.1155/2016/4054806. Epub 2016 May 12.
9
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.肝硬化患者血浆中抗凝药物对凝血酶生成的体外抑制差异
PLoS One. 2014 Feb 4;9(2):e88390. doi: 10.1371/journal.pone.0088390. eCollection 2014.
10
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.常规凝血检测会低估肝硬化患者血浆中依赖于抗凝血酶的药物水平，但不会低估直接抗凝药物的水平。
Br J Haematol. 2013 Dec;163(5):666-73. doi: 10.1111/bjh.12593. Epub 2013 Oct 8.